These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31658058)

  • 1. Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.
    Schelter BO; Shiells H; Baddeley TC; Rubino CM; Ganesan H; Hammel J; Vuksanovic V; Staff RT; Murray AD; Bracoud L; Riedel G; Gauthier S; Jia J; Bentham P; Kook K; Storey JMD; Harrington CR; Wischik CM
    J Alzheimers Dis; 2019; 72(3):931-946. PubMed ID: 31658058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.
    Shiells H; Schelter BO; Bentham P; Baddeley TC; Rubino CM; Ganesan H; Hammel J; Vuksanovic V; Staff RT; Murray AD; Bracoud L; Wischik DJ; Riedel G; Gauthier S; Jia J; Moebius HJ; Hardlund J; Kipps CM; Kook K; Storey JMD; Harrington CR; Wischik CM
    J Alzheimers Dis; 2020; 75(2):501-519. PubMed ID: 32280089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of hydromethylthionine as a treatment option for Alzheimer's disease.
    Hashweh NN; Bartochowski Z; Khoury R; Grossberg GT
    Expert Opin Pharmacother; 2020 Apr; 21(6):619-627. PubMed ID: 32037892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.
    Wischik CM; Bentham P; Gauthier S; Miller S; Kook K; Schelter BO
    J Prev Alzheimers Dis; 2022; 9(4):780-790. PubMed ID: 36281683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
    Wilcock GK; Gauthier S; Frisoni GB; Jia J; Hardlund JH; Moebius HJ; Bentham P; Kook KA; Schelter BO; Wischik DJ; Davis CS; Staff RT; Vuksanovic V; Ahearn T; Bracoud L; Shamsi K; Marek K; Seibyl J; Riedel G; Storey JMD; Harrington CR; Wischik CM
    J Alzheimers Dis; 2018; 61(1):435-457. PubMed ID: 29154277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model.
    Riedel G; Klein J; Niewiadomska G; Kondak C; Schwab K; Lauer D; Magbagbeolu M; Steczkowska M; Zadrozny M; Wydrych M; Cranston A; Melis V; Santos RX; Theuring F; Harrington CR; Wischik CM
    Curr Alzheimer Res; 2020; 17(3):285-296. PubMed ID: 32091331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.
    Gauthier S; Feldman HH; Schneider LS; Wilcock GK; Frisoni GB; Hardlund JH; Moebius HJ; Bentham P; Kook KA; Wischik DJ; Schelter BO; Davis CS; Staff RT; Bracoud L; Shamsi K; Storey JM; Harrington CR; Wischik CM
    Lancet; 2016 Dec; 388(10062):2873-2884. PubMed ID: 27863809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease.
    Wischik CM; Staff RT; Wischik DJ; Bentham P; Murray AD; Storey JM; Kook KA; Harrington CR
    J Alzheimers Dis; 2015; 44(2):705-20. PubMed ID: 25550228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier.
    Bentham P; Staff RT; Schelter BO; Shiells H; Harrington CR; Wischik CM
    J Alzheimers Dis; 2021; 83(3):1017-1023. PubMed ID: 34366349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease.
    Baddeley TC; McCaffrey J; Storey JM; Cheung JK; Melis V; Horsley D; Harrington CR; Wischik CM
    J Pharmacol Exp Ther; 2015 Jan; 352(1):110-8. PubMed ID: 25320049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia.
    Kile S; Au W; Parise C; Rose K; Donnel T; Hankins A; Chan M; Ghassemi A
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):106-112. PubMed ID: 26420886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine.
    Kondak C; Riedel G; Harrington CR; Wischik CM; Klein J
    J Neurochem; 2022 Jan; 160(2):172-184. PubMed ID: 34855998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Andreasson U; Zetterberg H; Blennow K;
    JAMA Neurol; 2017 May; 74(5):557-566. PubMed ID: 28346578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Lozupone M; Santamato A; Zecca C; Barulli MR; Bellomo A; Pilotto A; Daniele A; Greco A; Logroscino G
    Biomed Res Int; 2016; 2016():3245935. PubMed ID: 27429978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease.
    Deters KD; Risacher SL; Kim S; Nho K; West JD; Blennow K; Zetterberg H; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
    J Alzheimers Dis; 2017; 58(4):1245-1254. PubMed ID: 28550246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials.
    Kishi T; Matsunaga S; Oya K; Ikuta T; Iwata N
    Int J Neuropsychopharmacol; 2015 Jun; 18(12):. PubMed ID: 26091818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.
    Gibson GE; Luchsinger JA; Cirio R; Chen H; Franchino-Elder J; Hirsch JA; Bettendorff L; Chen Z; Flowers SA; Gerber LM; Grandville T; Schupf N; Xu H; Stern Y; Habeck C; Jordan B; Fonzetti P
    J Alzheimers Dis; 2020; 78(3):989-1010. PubMed ID: 33074237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.